- Mission [1]
- FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science
and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities
to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency
preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical
products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence
and accountability. The Dermatologic and Ophthalmic Drugs Advisory Committee supports FDA's strategic priorities by reviewing
and evaluating available data concerning the safety and effectiveness of marketed and investigational human drug products
for use in the treatment of dermatologic and ophthalmic disorders and makes appropriate recommendations to the Commissioner
of Food and Drugs. This supports the development of safe and effective new medical technologies, and advances the status of
the Agency as a science-based and science-led regulatory agency, providing global leadership in the protection of public health.
|
